← CATALYST PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $13.9m | $57.5m | $16.6m | $89.5m | $130.2m | $171.4m | $298.4m | $137.6m | $517.6m | $709.2m | |
| Prepaid Expense and Other Assets, Current | $1.0m | $1.2m | $1.6m | $4.4m | $8.3m | $4.4m | $5.2m | $12.5m | $21.0m | $21.2m | |
| Short-term Investments | $26.5m | $26.5m | $36.9m | $5.0m | $10.0m | $19.8m | $0 | $0 | — | — | |
| Inventory, Net | — | $0 | $56k | $2.0m | $4.7m | $7.9m | $6.8m | $15.6m | $19.5m | $37.2m | |
| Assets, Current | $41.5m | $85.2m | $55.2m | $111.4m | $159.2m | $210.1m | $320.8m | $219.3m | $623.6m | $894.0m | |
| Property, Plant and Equipment, Net | $244k | $191k | $245k | $210k | $130k | $959k | $847k | $1.2m | $1.4m | $1.0m | |
| Operating Lease, Right-of-Use Asset | — | — | — | $793k | $0 | $3.0m | $2.8m | $2.5m | $2.2m | $1.9m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | — | $10.5m | $6.0m | $6.6m | $10.4m | $53.5m | $65.5m | $126.5m | |
| Accrued Liabilities, Current | $1.2m | $2.3m | $7.2m | $20.0m | $18.5m | $24.3m | $53.6m | $61.3m | $104.1m | $135.9m | |
| Assets | $41.7m | $85.4m | $60.4m | $112.4m | $192.4m | $237.8m | $375.6m | $470.1m | $851.4m | $1.1b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $301k | $29k | $308k | $337k | $369k | $402k | $437k | |
| Accounts Payable, Current | $933k | $1.9m | $2.3m | $4.1m | $4.3m | $2.8m | $4.0m | $14.8m | $16.6m | $11.2m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $648k | $0 | $3.9m | $3.6m | $3.2m | $2.8m | $2.4m | |
| Dividends Payable, Current | — | — | — | $2 | — | — | — | — | — | — | |
| Liabilities, Current | $2.1m | $4.3m | $9.5m | $24.1m | $22.8m | $27.1m | $57.6m | $76.1m | $120.7m | $147.2m | |
| Other Liabilities, Noncurrent | — | — | — | — | — | — | $14.1m | $3.0m | $315k | $209k | |
| Deferred Tax Liabilities, Net | — | — | — | — | — | $1.6m | $1.3m | $1.8m | $3.1m | $2.8m | |
| Liabilities | $2.4m | $4.4m | $9.7m | $24.7m | $22.8m | $31.0m | $75.2m | $82.2m | $123.8m | $149.7m | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Common Stock, Value, Issued | $83k | $103k | $103k | $103k | $104k | $103k | $105k | $107k | $121k | $123k | |
| Additional Paid in Capital | $147.4m | $207.4m | $211.3m | $216.2m | $223.2m | $233.2m | $250.4m | $266.5m | $442.3m | $480.0m | |
| Retained Earnings (Accumulated Deficit) | ($108.1m) | ($126.6m) | ($160.6m) | ($128.7m) | ($53.7m) | ($26.3m) | $49.9m | $121.3m | $285.2m | $474.2m | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | — | — | ($20k) | $10k | $31k | ($148k) | $24k | $14k | $64k | $0 | |
| Stockholders' Equity Attributable to Parent | $39.3m | $81.0m | $50.8m | $87.6m | $169.6m | $206.8m | $300.4m | $387.9m | $727.6m | $954.3m | |
| Liabilities and Equity | $41.7m | $85.4m | $60.4m | $112.4m | $192.4m | $237.8m | $375.6m | $470.1m | $851.4m | $1.1b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.